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Histamine H2 receptor activity (CAMP generation) has been characterized in U-937 cells before and after 
retinoic acid-induced differentiation into monocyte-/macrophage-like c lls. The differentiation is associated 
with a decreased capacity of U-937 monocytes to generate CAMP under basal conditions or after cell surface 
receptor stimulation by histamine, isoproterenol and PGEi. In contrast, the potencies of the hormones are 
unchanged during monocytic maturation (E& values = 3.2-4.6 x 10v6 M histamine, 4.6- 7 x 10m9 
M isoproterenol, 2-4.6 x 10 -6 M PGEi). The data support the view that histamine and CAMP-inducing 
agents may control the proliferation and differentiation of normal and leukemic cells committed to mono- 
cytic maturation in man. They also raise the possibility that normal human monocytes also possess function- 
al H2 receptors and that histamine may be implicated in the regulation of monocyte/macrophage functions. 
Histamine H2 receptor Monocytic differentiation U-937 cell Monocyte-Macrophage-like cell 
1. INTRODUCTION 
We have recently demonstrated that the human 
promyelocytic leukemic HL-60 cells possess typical 
histamine HZ receptors [l] with pharmacological 
properties similar to those established in mature 
human peripheral neutrophils [2]. The HL-60 cells 
can be induced to differentiate into granulocyte- 
like cells by retinoic acid [3] or into monocyte- 
/macrophage-like cells in the presence of 
leucocyte-conditioned medium [4]. The human 
histiocytic lymphoma cell line U-937, which has 
the characteristics of immature monocytoid cells 
with monoblast-like characters [5] can also be 
primed for differentiation into monocyte- 
Imacrophage-like cells by treatment with retinoic 
acid [6]. This morphological maturation is accom- 
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panied by the apparition of biochemical and func- 
tional characteristics of mature monocytes, in- 
cluding nonspecific esterase staining, phago- 
cytosis, chemotaxis, hexose monophosphate shunt 
activity and the capacity to reduce nitroblue tetra- 
zolium (NBT). The U-937 system thus provides a 
model for the study of plasma membrane develop- 
ment and cell surface receptor expression during 
human mono&c differentiation. Since mono- 
blastic and promyelocytic progenitors originate 
from the common hemoblastic precursor, we have 
investigated the presence of histamine receptors in 
U-937 cells before and after monocytic differentia- 
tion by retinoic acid. Histamine receptor activity 
and specificity were evaluated by measurements of
CAMP levels in U-937 cells after adding histamine 
or its HI and Hz agonists and antagonists. Changes 
in CAMP production after histamine addition were 
compared to those obtained with the ubiquitous 
adenylate cyclase activators, isoproterenol and 
prostaglandins. A portion of this work has been 
described in [7]. 
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2. MATERIALS AND METHODS 
Histamine dihydro~hloride, ~phenhydramine 
(DPH), prostagl~dins Er (PGEr), L-isoprotere- 
nol, all-trans-fi-retinoic acid, NBT, 3-isobutyl-l- 
methylxanthine (IBMX) and cyclic adenosine 3 ‘- 
5 ’ -monophosphate (CAMP) were purchased from 
Sigma (St. Louis, MO), bovine serum albumin 
(fraction V) was from Miles Laboratories (Elkhart, 
IN). RPMI-1640 medium, fetal calf serum and 
antibiotics were from Flow Laboratories. Highly 
purified natural porcine VIP and crystallized por- 
cine glucagon (lot 421306) were, respectively, pur- 
chased from Professor V. Mutt @HI-Laboratory, 
Stockholm, Sweden) and from Novo Research In- 
stitute (Bagsvaerd, Denmark). Impromidine, 
(4-methyl)histamine (4-MH), 2-(2-aminoethyl)- 
thiazole (AET), 2-(2-pyridyl)ethylamine (PEA) 
and cimetidine were generous gifts from Dr R. 
Brimblecombe of Smith, Kline and French La- 
boratories (Welwyn Garden City, Hertfordshire, 
England). All other chemicals used were of the 
highest purity available. 
2.1. Ceil culture 
The U-937 cells, generously provided by Dr 
Breitman (National Cancer Institute, Bethesda, 
USA) were grown in continuous liquid suspension 
culture in RPM1 1640 medium supplemented with 
10% heat-inactivated fetal calf serum, 2 mM L- 
glutamine, streptomycin (100 pg/ml) and penicillin 
(100 IUlml). The cells are passaged at starting 
densities of l-2 x 16 cells/ml and were incubated 
at 37°C in a humidified atmosphere of 5% CO2 in 
air. Cells were harvested by centrifugation (200 x 
g, 5 min), washed twice in Krebs-Ringer phosphate 
buffer (KRP, pH 7.4) and finally resuspended in 
this buffer to a final concentration of 1-2 X lo6 
cells/ml for CAMP analysis. Cells were counted in 
a homocytometer chamber and cell viability was 
determined by trypan blue exclusion. Differential 
counts were performed on a minimum of 100 cells 
for each experiment. Cell viability was 85-95%, 
and incubation of U-937 cells (37°C for 
5-15-30 min) in the presence of 10v4 M 
isoproterenol, prostaglandins El, histamine or its 
analogs did not change this percentage. Differen- 
tiation of U-937 cells was induced by culturing the 
cells in the presence of 1 FM retinoic acid for 6 
days. Differentiation of U-937 cells was estimated 
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by a number of criteria [S], including mor- 
phological assessment on cytospin slide prepara- 
tions stained with May-Grunwald-Giemsa, reduc- 
tion of NBT, chemotaxis towards activated human 
serum in modified Boyden chambers, hexose 
monophosphate shunt activity, phagocytosis of 
heat-inactivated yeast cells and antibody- 
dependent cellular cytotoxicity. 
The HGT-1 cell line, provided by Dr Laboisse 
(Paris), was routinely cultured in Dulbecco’s 
modified Eagle’s medium, as in [9]. Adherent cells 
cultured in the absence or in presence of 1 PM 
retinoic acid for 7 days were removed from culture 
flasks with 0.02% EDTA. Cell viability was about 
90-95% after 7 days of cell culture in the absence 
or presence of 1 pM retinoic acid. 
2.2. Cyclic AMP assay 
In a standard assay, 150 ,& from the U-937 cell 
suspensions (l-2 x lo6 cells/ml, initial concentra- 
tion) were preincubated for 10 min at 37°C in 
250~1 Krebs Ringer phosphate buffer (pH 7.5) 
containing 1% BSA and 2 mM IBMX. The reac- 
tion was initiated by the addition of appropriate 
hormones or drugs (100 111). The reaction was 
stopped after 10 min incubation by adding 50 ,& 
11 N HCl04 and CAMP was determined by the 
radioimmunoassay method described in [2]. None 
of the agents used in the present study interfered 
with the assay of CAMP. 
2.3. Processing of the data and statistical anaiysis 
Absolute values are given as pmol CAMP pro- 
duced by lo6 cells. The apparent EGO and ZCSO 
potency values were the doses required to produce, 
respectively, 50% of the maximal stimulation or 
inhibition produced by the test agents. An- 
tagonism by H1 and HZ antihistamine was analyzed 
assuming competitive inhibition, according to the 
equation [lo] : 
Ki = ZCSO/(l + iS/l?C50), 
where: lui = the inhibition constant of the an- 
tagonist, and S = the histamine concentration. The 
data were normalized as the percentage of the 
response to a given concentration of histamine. 
Results were analyzed by standard methods using 
Student’s paired t-test. 
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3. RESULTS 
3.1. rnf~ue~ce of time and IBMX on hisiumine 
receptor activity in U-937 cells 
As shown in fig.1, basal CAMP levels in U-937 
cells, before (left) and after (right) monocytic dif- 
ferentiation by retinoic acid, stay constant (1.4 t 
0.26 and 1.05 t 0.22 pmol/106 cells, respectively) 
during the O-15 min incubation period at 37*C, in 
the absence of phosphodiesterase inhibitor. Addi- 
tion of lo-” M histamine produced a rapid (1 min) 
and significant (2.7- to 2.4-fold) production during 
5 min (respective peak values: 2.9 + 0.41 and 2.6 + 
0.43 pmol/106 cells), followed by a progressive 
decrease within differentiated U-937 cells. Addi- 
tion of the phosphodiesterase inhibitor IBMX 
from 0.1 to 2 mM potentiated remarkably the 
stimulatory effect of histamine in undifferentiated 
U-937 cells. The maximal difference between basal 
(5.1 + 0.9 pmol/106 cells} and histamine- 
stimulated CAMP levels (75.4 -+ 6.5 pmol/106 
cells, n = 4) was seen with 1 mM IBMX (fig.2). 
This concentration of phosphodiesterase inhibitor 
allowed us to study histamine receptor activity 
under conditions of equilibrium in U-937 cells 
since CAMP levels attained a piateau within 3 min, 
and remained constant for up to 15 min. It was 
Time, min. 
Fig.1. Effect of time on histamine receptor activity in 
U-937 cells (left) or U-937 monocytes (right), incubated 
in the absence of phosphodiesterase inhibitor. Cells 
(0.3-0.6 x lo6 per ml, fina con~n~ration) were 
preincubated at 37°C for 10 min in KRP buffer 
containing 1% BSA and then incubated for the time 
indicated in the absence (basal CAMP levels, 0) or 
presence (0) of 10m4 M histamine. Data are means f SE 
of the results from 4-7 experiments performed in 
[Effecters], -log M 
Fig.3. Effect of various concentrations of histamine, L- 
isoproterenol and PGEr on CAMP generation i  U-937 
cells (left) or U-937 monocytes (right). Cells were 
preincubated for 10 min at 37°C in the standard buffer 
containing IBMX and incubated for 10 min in the 
presence of histamine (o), isoproterenol (0) and PGEr 
(A). Data are means + SE of the results from 4-12 
duplicate or triplicate. experiments performed in duplicate or triplicate. 
100 VI = 
t - 
lm,M 1 s 
0 35 15 
Time, min. 
Fig.2. Effect of the phosphodiesterase inhibitor IBMX 
on histamine receptor activity in U-937 cells. Cells were 
preincubated for 10 min at 37°C in the standard KRP 
buffer containing various concentrations of IBMX, and 
incubated for the time indicated in the presence of 
10v4 M histamine. Data are means or SE of the results 
from 4 experiments performed in duplicate or triplicate. 
also verified that, in U-937 cells incubated in the 
absence or presence of 10e3 M histamine, CAMP 
generation was a linear function of cell concentra- 
tion from 0.08 to 1.2 x lo6 cells/ml (not shown). 
3.2. Comparative effect of histamine, isoprote- 
renal and ~~st~rnine 
Cyclic AMP production in U-937 cells incubated 
for 10 min at 37°C was stimulated by histamine 
over a range of lo-’ to 10m3 M (fig.3). Half- 
50 
25 
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Table 1 
Cyclic AMP production in U-937 cells and U-937 monocytic-like cells incubated under 
basal conditions or exposed to histamine, isoproterenol and prostaglandins 
Effecters CAMP (pmol/106 cells) 
U-937 cells U-937 monocytes 
Control 4.86 + 0.52 (22) 2.48 + 0.19 (12) 
Histamine (low4 M) 76.4 * 6.4 (12) 35.4 * 3.6 ( 5) 
Isoproterenol ( 10m6 M) 54 + 10 ( 6) 21 k1.5 (4) 
PGEi (1O-4 M) 75 * 5.4 ( 4) 31.3 * 3.9 ( 4) 
Cells were incubated at 37°C in the standard solution containing IBMX. After 10 min, 
the indicated agents were added and the incubation was continued for 10 min. The 
values are means rt SE of the number of separate xperiments indicated in parentheses 
maximal stimulations (EC50 values) were, respec- 
tively, observed at 3.16 or 4.6 x 10d6 M histamine 
in U-937 cells, before (left) and after (right) 
retinoic acid-induced monocytic differentiation. 
Basal CAMP levels in U-937 cells were significantly 
increased by 10m9 M isoproterenol or 10e7 M 
PGEi. The potency of isoproterenol and PGEr 
were similar in U-937 cells before (EC50 = 4.6 x 
10e9 M isoproterenol, 4.6 x 10e6 M PGEr) or 
after monocytic differentiation (EC50 = 7 x 
10e9 M and 2 x 10m6 M, respectively). Table 1 in- 
dicates that U-937 cell differentiation into mono- 
cyte-like cells is associated with a remarkable 
reduction of the capacity of cells to generate 
CAMP under basal or stimulated conditions. In 
contrast, vasoactive intestinal peptide and gluca- 
gon, two peptides having, respectively, specific 
receptor sites in T lymphocytes [11,12] and mono- 
cytes [13], are inactive in U-937 cells and U-937 
monocytes. It is therefore possible that functional 
glucagon receptors are expressed in more mature 
monocytes during myeloid differentiation. 
stimulation. In contrast, the Hz agonist im- 
promidine and the Hi agonist PEA were partial 
agonists of histamine, since they produced, respec- 
tively, only 22-26% and 34-44% of the maximal 
stimulation observed with histamine. The relative 
potencies of the Hr, Hz agonists studied has been 
compared in U-937 cells and U-937 monocytes 
(table 2). Fig.5 shows that the Hi antagonist DPH 
and the HZ antagonist cimetidine completely 
abolished in a monophasic manner CAMP produc- 
tion induced by 10m4 M histamine in U-937 cells 
and U-937 monocytes. Approximately 50% of the 
3.3. Comparative effect of histamine and [ Agonirtsl, -log M 
synthetic related analogs 
The effect of impromidine and 4-MH, two 
Hz-selective agonists, and of PEA and AET, two 
Hr-selective agonists were compared to histamine 
receptor activity in U-937 cells (fig.4), before (left) 
and after (right) retinoic acid-induced monocytic 
differentiation. The HZ agonist 4-MH and the Hr 
agonist AET produced parallel dose-response 
curves to histamine with a similar extent of CAMP 
Fig.4. Receptor specificity of histamine-induced CAMP 
production in U-937 cells (left) and U-937 monocytes 
(right) toward various histamine Hr or Hz agonists. Cells 
were preincubated for 10 min at 37°C in the standard 
buffer containing IBMX and incubated for 10 min after 
addition of histamine (0) or its Hz agonists 
impromidine (I, v), 4-MH (0) and Hr agonists AET 
(A), PEA (9). Data are means f SE of the results from 
4-6 experiments performed in duplicate or triplicate. 
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Table 2 
Comparison of the relative potencies of histamine and its Hr or H2 agonists on CAMP 
production in U-937 celis and U-937 monocytes 
Cells Agonists 
May 1985 
Impromidine H UXso) 4-MH AET PEA 
U-937 cells 2960 100 (7.4 x 1O-6 M) 23 2.3 1.3 
U-937 monocytes 2700 100 (4.6 x lO-6 M) 15 1 0.7 
The relative potency of each agonist was established as the ratio: EC50 for histamine/E& 
for agonist x 100. The potency (ECso) of histamine: H in each preparation is indicated in 
parentheses 
response was inhibited with an XSO of 2.15 x 
10m5 M cimetidine, giving a K; value of 0.66 x 
10m6 M. The Hr antagonist DPH also produced a 
dose-related inhibition, but with 100-200 times 
higher concentrations (IGo = 2.5 x low4 M in 
U-937 cells and 4.7 x low4 M DPH in U-937 
monocytes), giving Ki values of 0.76 and 1.44 x 
10m4 M DPH, respectively. 
[Antagonists],-log M 
Fig.5. Receptor specificity of histamine-induced CAMP 
production in U-937 cells (left) and U-937 monocytes 
(right) toward histamine Hr or Hz antagonists. After a 
lo-min incubation period at 37°C. histamine alone 
(1O-4 M, control stimulation) or in combination with the 
Hz antagonist cimetidine (C, e) or the Hr antagonist 
DPH (DPH, A) were added and the incubation was 
continued for 10 min in the presence of IBMX, as 
indicated in section 2. Cyclic AMP production in control 
cells (0). Results are expressed as the percentage of 
CAMP production elicited by histamine alone. Data are 
means f SE of the results from 4 experiments performed 
in duplicate or triplicate. 
4. DISCUSSION 
Our current studies demonstrate the presence of 
functional and specific HZ receptors for histamine 
in the human monoblastic U-937 cells, before and 
after retinoic acid-induced differentiation into 
monocyte-/macrophage-like cells. The phar- 
macological analysis of the effect of histamine and 
its Hr or Hz agonists in U-937 cells and U-937 
monocytes shows a potency sequence (I > H > 
4-MH > AET > PEA) characteristic of the Hz type 
histamine receptor. The same order of potency (Hz 
> Hi) has been established for histamine HZ recep- 
tor activity in human promyelocytic HL-60 cells 
[ 11, in mature human neutrophils [2] as well as in 
other tissues bearing HZ receptors [14,15]. In con- 
trast, an inverse sequence (Hr > HZ) was found for 
Hr receptors [16]. The measured IGO and 
calculated Ki values for the Hz antagonist 
cimetidine (Ki = 0.66 x 10e6 M) and the Hr an- 
tagonist DPH (Ki = 0.76-1.44 x 10F4 M) indicate 
that DPH was approx. l-2 x lo2 times less potent 
than cimetidine in inhibiting histamine receptor ac- 
tivity in U-937 cells and U-937 monocytes. The in- 
hibition constants obtained here are comparable to 
the relative affinities of these two antagonists (HZ 
> Hr) for HZ receptors [ 1,2] in human neutrophils 
(Ki = 0.4 x low6 M cimetidine and 65 x 10m6 M 
DPH) and human promyeloc~ic HL-60 cells (Ki = 
0.65 and 51 x 10m6 M, respectively). 
The relative potencies of histamine and the 
Hr,H2 receptor agonists and antagonists studied 
are remarkably similar in U-937 cells before and 
after differentiation with retinoic acid, indicating 
that the structural requirements of the Hz receptor 
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for adenylate cyclase activation are unchanged 
during monocytic/macrophage maturation. The 
same observation is made for PGEr and 
isoproterenol. In contrast, the differentiation is 
associated with a decreased capacity of the U-937 
monocytes to generate CAMP under basal condi- 
tions or after cell surface receptor activation by 
histamine, isoproterenol and prostaglandins. Such 
a phenomenon has been described previously dur- 
ing the granulocytic differentiation of the human 
promyelocytic cell line HL-60 by retinoic acid [ 171, 
as well as for the comparison between differen- 
tiated HL-60 cells and mature human peripheral 
neutrophils [1,2]. It is therefore possible that 
histamine, isoproterenol or prostaglandins may 
play a role in the regulation of proliferation/dif- 
ferentiation of human monocytic precursor cells 
since dibutyryl CAMP or the CAMP-inducing agent 
cholera toxin have been shown to act synergistical- 
ly with retinoic acid or 1,25_dihydroxyvitamin D3 
to induce differentiation of HL-60 or U-937 cells 
[6,18,19]. Changes in histamine receptor activity 
during retinoic acid-induced monocyte differentia- 
tion of U-937 cells are well related to cell differen- 
tiation since there is no change in HZ receptor ac- 
tivity [14] and no morphological differentiation [9] 
in the human gastric cancer HGT-1 cells when they 
are cultured under the same conditions with 
retinoic acid. 
Histamine receptors (HI, Hz and a third type) 
have been identified in alveolar macrophages [20] 
as well as in a variety of circulating human blood 
cells, including lymphocytes [21-231, platelets 
[24,25], eosinophil [26], basophil [27] and 
neutrophil [2,28] leukocytes. Since the role of 
histamine in the inflammatory and immune 
response is now well accepted [29], the presence of 
cell surface receptors for histamine in the human 
monocytic U-937 cells also raises the possibility 
that normal human monocytes possess functional 
histamine Hz receptors linked to a biological 
response. Studies are now in progress on isolated 
human peripheral monocytes to attempt to con- 
firm this hypothesis. 
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